May 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday began discussing Pfizer Inc's (PFE.N) experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers.
